Schrodinger
Computational drug designing for pharmaceutical and biotechnology research.
Launch date
Employees
Market cap
AUD2.3b
Enterprise valuation
AUD1.9b (Public information from Sep 2024)
Share price
$19.72 SDGR
New York City New York (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 108m | 138m | 181m | 217m | 210m | 261m | 302m |
| % growth | 26 % | 28 % | 31 % | 20 % | (3 %) | 24 % | 16 % |
| EBITDA | (85.5m) | (120m) | (124m) | (225m) | (197m) | (175m) | (154m) |
| % EBITDA margin | (79 %) | (87 %) | (69 %) | (104 %) | (94 %) | (67 %) | (51 %) |
| Profit | (24.5m) | (100m) | (149m) | 40.7m | (174m) | (176m) | (164m) |
| % profit margin | (23 %) | (73 %) | (82 %) | 19 % | (83 %) | (68 %) | (54 %) |
| EV / revenue | 45.0x | 13.7x | 4.9x | 11.9x | 4.8x | 4.0x | 3.6x |
| EV / EBITDA | -56.8x | -15.8x | -7.1x | -11.4x | -5.2x | -5.9x | -7.2x |
| R&D budget | 64.7m | 90.9m | 126m | 182m | - | - | - |
| R&D % of revenue | 60 % | 66 % | 70 % | 84 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$10.0m | Late VC | ||
$20.0m | Growth Equity VC | ||
$22.0m | Growth Equity VC | ||
| N/A | $80.0m | Late VC | |
* | $85.0m | Series E | |
$110m | Series F | ||
* | N/A | $232m | IPO |
* | N/A | $347m | Post IPO Equity |
* | $4.9m | Grant | |
* | $10.0m | Grant | |
| Total Funding | AUD576m | ||
Related Content
Recent News about Schrodinger
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Schrodinger
Edit
ACQUISITION by Eli Lilly Jul 2024
ACQUISITION by Schrodinger Jan 2022
